Lv21
152 积分 2022-01-04 加入
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
4小时前
已完结
GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency
1个月前
已完结
Molecular glue neferine induces BAP31 homodimerisation to disrupt endoplasmic reticulum–mitochondria crosstalk for anti‐neuroinflammation in ischaemic stroke
1个月前
已完结
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
1个月前
已完结
Mechanism by which the molecular glue-like verteporfin induces IRE1α dimerization and activation to synergize with AKT inhibition in breast cancer
2个月前
已完结
Molecular glues evolve from serendipity to rational design
2个月前
已完结
Neo‐Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein
2个月前
已完结
Synthetic and Medicinal Chemistry Perspectives on Cereblon‐Binding Molecular Glue Degraders: Recent Advances and Emerging Trends
2个月前
已完结
Discovery and Evaluation of a PROTAC Degrader Targeting SAMHD1 for the Treatment of Pulmonary Fibrosis
3个月前
已完结
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
4个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
11个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
11个月前
已采纳
皖公网安备34019202002308
